Literature DB >> 28679962

Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction.

Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K Liao.   

Abstract

Although left ventricular (LV) diastolic dysfunction is often associated with hypertension, little is known regarding its underlying pathophysiological mechanism. Here, we show that the actin cytoskeletal regulator, Rho-associated coiled-coil containing kinase-2 (ROCK2), is a critical mediator of LV diastolic dysfunction. In response to angiotensin II (Ang II), mutant mice with fibroblast-specific deletion of ROCK2 (ROCK2Postn-/-) developed less LV wall thickness and fibrosis, along with improved isovolumetric relaxation. This corresponded with decreased connective tissue growth factor (CTGF) and fibroblast growth factor-2 (FGF2) expression in the hearts of ROCK2Postn-/- mice. Indeed, knockdown of ROCK2 in cardiac fibroblasts leads to decreased expression of CTGF and secretion of FGF2, and cardiomyocytes incubated with conditioned media from ROCK2-knockdown cardiac fibroblasts exhibited less hypertrophic response. In contrast, mutant mice with elevated fibroblast ROCK activity exhibited enhanced Ang II-stimulated cardiac hypertrophy and fibrosis. Clinically, higher leukocyte ROCK2 activity was observed in patients with diastolic dysfunction compared with age- and sex-matched controls, and correlated with higher grades of diastolic dysfunction by echocardiography. These findings indicate that fibroblast ROCK2 is necessary to cause cardiac hypertrophy and fibrosis through the induction CTGF and FGF2, and they suggest that targeting ROCK2 may have therapeutic benefits in patients with LV diastolic dysfunction.

Entities:  

Keywords:  Cardiology

Year:  2017        PMID: 28679962      PMCID: PMC5499369          DOI: 10.1172/jci.insight.93187

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  53 in total

1.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012.

Authors:  Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Anne I Dipchand; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2012-10       Impact factor: 10.247

3.  ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice.

Authors:  O Nakagawa; K Fujisawa; T Ishizaki; Y Saito; K Nakao; S Narumiya
Journal:  FEBS Lett       Date:  1996-08-26       Impact factor: 4.124

4.  Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis.

Authors:  Ying-Min Zhang; Jacqueline Bo; George E Taffet; Jiang Chang; Jianjian Shi; Anilkumar K Reddy; Lloyd H Michael; Michael D Schneider; Mark L Entman; Robert J Schwartz; Lei Wei
Journal:  FASEB J       Date:  2006-05       Impact factor: 5.191

5.  CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis.

Authors:  M M Chen; A Lam; J A Abraham; G F Schreiner; A H Joly
Journal:  J Mol Cell Cardiol       Date:  2000-10       Impact factor: 5.000

6.  Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells.

Authors:  Wenjian Wang; Yin Wang; Jianyin Long; Jinrong Wang; Sandra B Haudek; Paul Overbeek; Benny H J Chang; Paul T Schumacker; Farhad R Danesh
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

7.  Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death.

Authors:  Dean Thumkeo; Jeongsin Keel; Toshimasa Ishizaki; Masaya Hirose; Kimiko Nonomura; Hiroko Oshima; Masanobu Oshima; Makoto M Taketo; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

8.  Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart.

Authors:  Paige Snider; Robert B Hinton; Ricardo A Moreno-Rodriguez; Jian Wang; Rhonda Rogers; Andrew Lindsley; Fang Li; David A Ingram; Donald Menick; Loren Field; Anthony B Firulli; Jeffery D Molkentin; Roger Markwald; Simon J Conway
Journal:  Circ Res       Date:  2008-02-22       Impact factor: 17.367

Review 9.  Fibroblast-mediated pathways in cardiac hypertrophy.

Authors:  Katsuhito Fujiu; Ryozo Nagai
Journal:  J Mol Cell Cardiol       Date:  2014-01-31       Impact factor: 5.000

10.  Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart.

Authors:  Hind Lal; Firdos Ahmad; Jibin Zhou; Justine E Yu; Ronald J Vagnozzi; Yuanjun Guo; Daohai Yu; Emily J Tsai; James Woodgett; Erhe Gao; Thomas Force
Journal:  Circulation       Date:  2014-06-04       Impact factor: 29.690

View more
  26 in total

1.  TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation.

Authors:  Ravi K Adapala; Anantha K Kanugula; Sailaja Paruchuri; William M Chilian; Charles K Thodeti
Journal:  Basic Res Cardiol       Date:  2020-01-10       Impact factor: 17.165

2.  SLIT3 deficiency attenuates pressure overload-induced cardiac fibrosis and remodeling.

Authors:  Lianghui Gong; Shuyun Wang; Li Shen; Catherine Liu; Mena Shenouda; Baolei Li; Xiaoxiao Liu; John A Shaw; Alan L Wineman; Yifeng Yang; Dingding Xiong; Anne Eichmann; Sylvia M Evans; Stephen J Weiss; Ming-Sing Si
Journal:  JCI Insight       Date:  2020-06-18

3.  Different roles of myocardial ROCK1 and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in mice.

Authors:  Shinichiro Sunamura; Kimio Satoh; Ryo Kurosawa; Tomohiro Ohtsuki; Nobuhiro Kikuchi; Md Elias-Al-Mamun; Toru Shimizu; Shohei Ikeda; Kota Suzuki; Taijyu Satoh; Junichi Omura; Masamichi Nogi; Kazuhiko Numano; Mohammad Abdul Hai Siddique; Satoshi Miyata; Masahito Miura; Hiroaki Shimokawa
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

Review 4.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Increasing Cardiomyocyte Atrogin-1 Reduces Aging-Associated Fibrosis and Regulates Remodeling in Vivo.

Authors:  Roberto Mota; Traci L Parry; Cecelia C Yates; Zhaoyan Qiang; Samuel C Eaton; Jean Marie Mwiza; Deepthi Tulasi; Jonathan C Schisler; Cam Patterson; Tania Zaglia; Marco Sandri; Monte S Willis
Journal:  Am J Pathol       Date:  2018-05-23       Impact factor: 4.307

6.  Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.

Authors:  Brian Yu; Nikola Sladojevic; John E Blair; James K Liao
Journal:  Expert Opin Ther Targets       Date:  2020-01-09       Impact factor: 6.902

Review 7.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

Review 8.  RAS inhibition in resident fibroblast biology.

Authors:  Alexandra M Garvin; Bilal S Khokhar; Michael P Czubryt; Taben M Hale
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

9.  IGF-1 protects against angiotensin II-induced cardiac fibrosis by targeting αSMA.

Authors:  Sangmi Ock; Woojin Ham; Chae Won Kang; Hyun Kang; Wang Soo Lee; Jaetaek Kim
Journal:  Cell Death Dis       Date:  2021-07-09       Impact factor: 8.469

Review 10.  Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function.

Authors:  Nehal J Patel; Drew M Nassal; Daniel Gratz; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2020-11-23       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.